Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""IMMUNE checkpoint inhibitors"" wg kryterium: Temat


Tytuł :
T-cell-based Immunotherapies for Haematological Cancers, Part A: A SWOT Analysis of Immune Checkpoint Inhibitors (ICIs) and Bispecific T-Cell Engagers (BiTEs).
Autorzy :
Rallis KS; Barts Cancer Institute, Queen Mary University of London, London, U.K.; .; Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, U.K.
Hillyar CRT; Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, U.K.
Sideris M; Women's Health Research Unit, Queen Mary University of London, London, U.K.
Davies JK; Barts Cancer Institute, Queen Mary University of London, London, U.K.
Pokaż więcej
Źródło :
Anticancer research [Anticancer Res] 2021 Mar; Vol. 41 (3), pp. 1123-1141.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Antibodies, Bispecific/*immunology
Hematologic Neoplasms/*drug therapy
Immune Checkpoint Inhibitors/*therapeutic use
Immunotherapy/*methods
T-Lymphocytes/*immunology
Antibodies, Bispecific/adverse effects ; Antibodies, Bispecific/therapeutic use ; CTLA-4 Antigen/physiology ; Humans ; Immune Checkpoint Inhibitors/adverse effects ; Immune Checkpoint Inhibitors/pharmacology ; Programmed Cell Death 1 Receptor/physiology
Czasopismo naukowe
Tytuł :
Rheumatic Complications of Immune Checkpoint Inhibitors.
Autorzy :
Ghosh N; Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, USA.
Bass AR; Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, USA. Electronic address: .
Pokaż więcej
Źródło :
The Medical clinics of North America [Med Clin North Am] 2021 Mar; Vol. 105 (2), pp. 227-245.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Immune Checkpoint Inhibitors*/immunology
Immune Checkpoint Inhibitors*/pharmacology
Rheumatic Diseases*/chemically induced
Rheumatic Diseases*/immunology
Rheumatic Diseases*/therapy
Neoplasms/*drug therapy
Antineoplastic Agents/immunology ; Antineoplastic Agents/pharmacology ; Humans
Czasopismo naukowe
Tytuł :
Predicting and Preventing Immune Checkpoint Inhibitor Toxicity: Targeting Cytokines.
Autorzy :
Kang JH; Sean N. Parker Autoimmune Research Laboratory and Diabetes Center, University of California San Francisco, San Francisco, CA, USA.
Bluestone JA; Sean N. Parker Autoimmune Research Laboratory and Diabetes Center, University of California San Francisco, San Francisco, CA, USA; Sonoma Biotherapeutics, South San Francisco, CA, USA.
Young A; Sean N. Parker Autoimmune Research Laboratory and Diabetes Center, University of California San Francisco, San Francisco, CA, USA; QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia. Electronic address: .
Pokaż więcej
Źródło :
Trends in immunology [Trends Immunol] 2021 Apr; Vol. 42 (4), pp. 293-311. Date of Electronic Publication: 2021 Mar 10.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
MeSH Terms :
Cytokines*
Immune Checkpoint Inhibitors*/adverse effects
Neoplasms*/drug therapy
Humans ; Immunotherapy/adverse effects
Czasopismo naukowe
Tytuł :
Outcome of patients with advanced upper tract urothelial carcinoma treated with immune checkpoint inhibitors: A systematic review and meta-analysis.
Autorzy :
Bersanelli M; Medicine and Surgery Department, University of Parma, Parma, Italy; Medical Oncology Unit, University Hospital of Parma, Parma, Italy. Electronic address: .
Buti S; Medical Oncology Unit, University Hospital of Parma, Parma, Italy.
Giannatempo P; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Raggi D; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Necchi A; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Leonetti A; Medicine and Surgery Department, University of Parma, Parma, Italy; Medical Oncology Unit, University Hospital of Parma, Parma, Italy.
Banna GL; Portsmouth Hospitals NHS Trust, Portsmouth, UK.
Petrelli F; Medical Oncology Unit, ASST Bergamo Ovest, Treviglio, BG, Italy.
Pokaż więcej
Źródło :
Critical reviews in oncology/hematology [Crit Rev Oncol Hematol] 2021 Mar; Vol. 159, pp. 103241. Date of Electronic Publication: 2021 Feb 02.
Typ publikacji :
Journal Article; Meta-Analysis; Review; Systematic Review
MeSH Terms :
Carcinoma, Transitional Cell*/drug therapy
Immune Checkpoint Inhibitors*
Humans ; Prospective Studies
Czasopismo naukowe
Tytuł :
Fingolimod and tumor-infiltrating lymphocytes in checkpoint-inhibitor treated cancer patients.
Autorzy :
Hasan Ali O; Department of Medical Genetics, Life Sciences Institute, University of British Columbia, Vancouver, Canada.; Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.; Institute of Immunobiology, Kantonsspital St. Gallen, St. Gallen, Switzerland.
Berner F; Institute of Immunobiology, Kantonsspital St. Gallen, St. Gallen, Switzerland.
Ackermann CJ; Department of Oncology and Hematology, Spital STS AG, Thun, Switzerland.
Ring SS; Institute of Immunobiology, Kantonsspital St. Gallen, St. Gallen, Switzerland.
Moulin A; Department of Ophthalmology, L'Hôpital Ophtalmique Jules-Gonin, Lausanne, Switzerland.
Müller J; Department of Nuclear Medicine, Kantonsspital St. Gallen, St. Gallen, Switzerland.
Markert E; Institute of Pathology, Kantonsspital St. Gallen, St. Gallen, Switzerland.
Pop OT; Institute of Immunobiology, Kantonsspital St. Gallen, St. Gallen, Switzerland.
Müller S; Department of Neurology, Kantonsspital St. Gallen, St. Gallen, Switzerland.
Diem S; Department of Oncology and Hematology, Kantonsspital St. Gallen, St. Gallen, Switzerland.; Department of Oncology and Hematology, Spital Grabs, Grabs, Switzerland.
Hundsberger T; Department of Neurology, Kantonsspital St. Gallen, St. Gallen, Switzerland.
Flatz L; Department of Dermatology, University Hospital Zurich, Zurich, Switzerland. .; Institute of Immunobiology, Kantonsspital St. Gallen, St. Gallen, Switzerland. .; Department of Oncology and Hematology, Kantonsspital St. Gallen, St. Gallen, Switzerland. .; Department of Oncology and Hematology, Spital Grabs, Grabs, Switzerland. .; Department of Dermatology, Venerology and Allergology, Kantonsspital St. Gallen, Rorschacher Strasse 95, 9007, St. Gallen, Switzerland. .
Pokaż więcej
Źródło :
Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2021 Feb; Vol. 70 (2), pp. 563-568. Date of Electronic Publication: 2020 Aug 17.
Typ publikacji :
Case Reports; Journal Article
MeSH Terms :
Fingolimod Hydrochloride/*therapeutic use
Immune Checkpoint Inhibitors/*therapeutic use
Immunosuppressive Agents/*therapeutic use
Lymphocytes/*immunology
Lymphocytes, Tumor-Infiltrating/*immunology
Neoplasms/*drug therapy
Female ; Fingolimod Hydrochloride/pharmacology ; Humans ; Immune Checkpoint Inhibitors/pharmacology ; Immunosuppressive Agents/pharmacology ; Middle Aged ; Neoplasms/immunology
Czasopismo naukowe
Tytuł :
Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer.
Autorzy :
Kelly RJ; From the Charles A. Sammons Cancer Center at Baylor University Medical Center, Dallas (R.J.K.), and the University of Texas M.D. Anderson Cancer Center, Houston (J.A.A.); Jagiellonian University Medical College, John Paul II Hospital, Krakow, Poland (J.K., P.K.); the University Hospital Cologne, Department of Internal Medicine, Center for Integrated Oncology Aachen-Bonn-Cologne-Duesseldorf, Gastrointestinal Cancer Group Cologne, Cologne (T.Z.), and University Medical Center of Johannes Gutenberg-University Mainz (M.M.) - both in Germany; University Hospitals Gasthuisberg Leuven and KU Leuven, Leuven (E.V.C.), and Ghent University Hospital, Ghent (K.G.) - both in Belgium; University Lille, Claude Huriez University Hospital, Lille (G.P.), and Pontchaillou University Hospital, Department of Gastroenterology, University of Rennes 1, INSERM Unité 1242, Rennes (A.L.) - both in France; Fundación Favaloro, Buenos Aires (G.M.); Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore (J.F.); Akita University Hospital, Akita, Japan (S.M.); Duke Cancer Institute, Durham, NC (H.U.); Princess Margaret Cancer Centre, Toronto (E.E.), and Queen Elizabeth II Health Sciences Centre, Halifax, NS (S.S.) - both in Canada; the Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam (C.G.); Florida Cancer Specialists and Research Institute, Fort Myers (S.Z.); University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco (A.H.K.); St. John of God Murdoch Hospital, Murdoch, WA, Australia (K.F.); Sfantul Nectarie Oncology Center, Craiova, Romania (M.S.); Bristol Myers Squibb, Princeton, NJ (J.Z., L.Z., M.L., P.S., K.K.); and Dana-Farber Cancer Institute, Boston (J.M.C.).
Ajani JA; From the Charles A. Sammons Cancer Center at Baylor University Medical Center, Dallas (R.J.K.), and the University of Texas M.D. Anderson Cancer Center, Houston (J.A.A.); Jagiellonian University Medical College, John Paul II Hospital, Krakow, Poland (J.K., P.K.); the University Hospital Cologne, Department of Internal Medicine, Center for Integrated Oncology Aachen-Bonn-Cologne-Duesseldorf, Gastrointestinal Cancer Group Cologne, Cologne (T.Z.), and University Medical Center of Johannes Gutenberg-University Mainz (M.M.) - both in Germany; University Hospitals Gasthuisberg Leuven and KU Leuven, Leuven (E.V.C.), and Ghent University Hospital, Ghent (K.G.) - both in Belgium; University Lille, Claude Huriez University Hospital, Lille (G.P.), and Pontchaillou University Hospital, Department of Gastroenterology, University of Rennes 1, INSERM Unité 1242, Rennes (A.L.) - both in France; Fundación Favaloro, Buenos Aires (G.M.); Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore (J.F.); Akita University Hospital, Akita, Japan (S.M.); Duke Cancer Institute, Durham, NC (H.U.); Princess Margaret Cancer Centre, Toronto (E.E.), and Queen Elizabeth II Health Sciences Centre, Halifax, NS (S.S.) - both in Canada; the Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam (C.G.); Florida Cancer Specialists and Research Institute, Fort Myers (S.Z.); University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco (A.H.K.); St. John of God Murdoch Hospital, Murdoch, WA, Australia (K.F.); Sfantul Nectarie Oncology Center, Craiova, Romania (M.S.); Bristol Myers Squibb, Princeton, NJ (J.Z., L.Z., M.L., P.S., K.K.); and Dana-Farber Cancer Institute, Boston (J.M.C.).
Kuzdzal J; From the Charles A. Sammons Cancer Center at Baylor University Medical Center, Dallas (R.J.K.), and the University of Texas M.D. Anderson Cancer Center, Houston (J.A.A.); Jagiellonian University Medical College, John Paul II Hospital, Krakow, Poland (J.K., P.K.); the University Hospital Cologne, Department of Internal Medicine, Center for Integrated Oncology Aachen-Bonn-Cologne-Duesseldorf, Gastrointestinal Cancer Group Cologne, Cologne (T.Z.), and University Medical Center of Johannes Gutenberg-University Mainz (M.M.) - both in Germany; University Hospitals Gasthuisberg Leuven and KU Leuven, Leuven (E.V.C.), and Ghent University Hospital, Ghent (K.G.) - both in Belgium; University Lille, Claude Huriez University Hospital, Lille (G.P.), and Pontchaillou University Hospital, Department of Gastroenterology, University of Rennes 1, INSERM Unité 1242, Rennes (A.L.) - both in France; Fundación Favaloro, Buenos Aires (G.M.); Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore (J.F.); Akita University Hospital, Akita, Japan (S.M.); Duke Cancer Institute, Durham, NC (H.U.); Princess Margaret Cancer Centre, Toronto (E.E.), and Queen Elizabeth II Health Sciences Centre, Halifax, NS (S.S.) - both in Canada; the Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam (C.G.); Florida Cancer Specialists and Research Institute, Fort Myers (S.Z.); University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco (A.H.K.); St. John of God Murdoch Hospital, Murdoch, WA, Australia (K.F.); Sfantul Nectarie Oncology Center, Craiova, Romania (M.S.); Bristol Myers Squibb, Princeton, NJ (J.Z., L.Z., M.L., P.S., K.K.); and Dana-Farber Cancer Institute, Boston (J.M.C.).
Zander T; From the Charles A. Sammons Cancer Center at Baylor University Medical Center, Dallas (R.J.K.), and the University of Texas M.D. Anderson Cancer Center, Houston (J.A.A.); Jagiellonian University Medical College, John Paul II Hospital, Krakow, Poland (J.K., P.K.); the University Hospital Cologne, Department of Internal Medicine, Center for Integrated Oncology Aachen-Bonn-Cologne-Duesseldorf, Gastrointestinal Cancer Group Cologne, Cologne (T.Z.), and University Medical Center of Johannes Gutenberg-University Mainz (M.M.) - both in Germany; University Hospitals Gasthuisberg Leuven and KU Leuven, Leuven (E.V.C.), and Ghent University Hospital, Ghent (K.G.) - both in Belgium; University Lille, Claude Huriez University Hospital, Lille (G.P.), and Pontchaillou University Hospital, Department of Gastroenterology, University of Rennes 1, INSERM Unité 1242, Rennes (A.L.) - both in France; Fundación Favaloro, Buenos Aires (G.M.); Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore (J.F.); Akita University Hospital, Akita, Japan (S.M.); Duke Cancer Institute, Durham, NC (H.U.); Princess Margaret Cancer Centre, Toronto (E.E.), and Queen Elizabeth II Health Sciences Centre, Halifax, NS (S.S.) - both in Canada; the Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam (C.G.); Florida Cancer Specialists and Research Institute, Fort Myers (S.Z.); University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco (A.H.K.); St. John of God Murdoch Hospital, Murdoch, WA, Australia (K.F.); Sfantul Nectarie Oncology Center, Craiova, Romania (M.S.); Bristol Myers Squibb, Princeton, NJ (J.Z., L.Z., M.L., P.S., K.K.); and Dana-Farber Cancer Institute, Boston (J.M.C.).
Van Cutsem E; From the Charles A. Sammons Cancer Center at Baylor University Medical Center, Dallas (R.J.K.), and the University of Texas M.D. Anderson Cancer Center, Houston (J.A.A.); Jagiellonian University Medical College, John Paul II Hospital, Krakow, Poland (J.K., P.K.); the University Hospital Cologne, Department of Internal Medicine, Center for Integrated Oncology Aachen-Bonn-Cologne-Duesseldorf, Gastrointestinal Cancer Group Cologne, Cologne (T.Z.), and University Medical Center of Johannes Gutenberg-University Mainz (M.M.) - both in Germany; University Hospitals Gasthuisberg Leuven and KU Leuven, Leuven (E.V.C.), and Ghent University Hospital, Ghent (K.G.) - both in Belgium; University Lille, Claude Huriez University Hospital, Lille (G.P.), and Pontchaillou University Hospital, Department of Gastroenterology, University of Rennes 1, INSERM Unité 1242, Rennes (A.L.) - both in France; Fundación Favaloro, Buenos Aires (G.M.); Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore (J.F.); Akita University Hospital, Akita, Japan (S.M.); Duke Cancer Institute, Durham, NC (H.U.); Princess Margaret Cancer Centre, Toronto (E.E.), and Queen Elizabeth II Health Sciences Centre, Halifax, NS (S.S.) - both in Canada; the Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam (C.G.); Florida Cancer Specialists and Research Institute, Fort Myers (S.Z.); University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco (A.H.K.); St. John of God Murdoch Hospital, Murdoch, WA, Australia (K.F.); Sfantul Nectarie Oncology Center, Craiova, Romania (M.S.); Bristol Myers Squibb, Princeton, NJ (J.Z., L.Z., M.L., P.S., K.K.); and Dana-Farber Cancer Institute, Boston (J.M.C.).
Piessen G; From the Charles A. Sammons Cancer Center at Baylor University Medical Center, Dallas (R.J.K.), and the University of Texas M.D. Anderson Cancer Center, Houston (J.A.A.); Jagiellonian University Medical College, John Paul II Hospital, Krakow, Poland (J.K., P.K.); the University Hospital Cologne, Department of Internal Medicine, Center for Integrated Oncology Aachen-Bonn-Cologne-Duesseldorf, Gastrointestinal Cancer Group Cologne, Cologne (T.Z.), and University Medical Center of Johannes Gutenberg-University Mainz (M.M.) - both in Germany; University Hospitals Gasthuisberg Leuven and KU Leuven, Leuven (E.V.C.), and Ghent University Hospital, Ghent (K.G.) - both in Belgium; University Lille, Claude Huriez University Hospital, Lille (G.P.), and Pontchaillou University Hospital, Department of Gastroenterology, University of Rennes 1, INSERM Unité 1242, Rennes (A.L.) - both in France; Fundación Favaloro, Buenos Aires (G.M.); Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore (J.F.); Akita University Hospital, Akita, Japan (S.M.); Duke Cancer Institute, Durham, NC (H.U.); Princess Margaret Cancer Centre, Toronto (E.E.), and Queen Elizabeth II Health Sciences Centre, Halifax, NS (S.S.) - both in Canada; the Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam (C.G.); Florida Cancer Specialists and Research Institute, Fort Myers (S.Z.); University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco (A.H.K.); St. John of God Murdoch Hospital, Murdoch, WA, Australia (K.F.); Sfantul Nectarie Oncology Center, Craiova, Romania (M.S.); Bristol Myers Squibb, Princeton, NJ (J.Z., L.Z., M.L., P.S., K.K.); and Dana-Farber Cancer Institute, Boston (J.M.C.).
Mendez G; From the Charles A. Sammons Cancer Center at Baylor University Medical Center, Dallas (R.J.K.), and the University of Texas M.D. Anderson Cancer Center, Houston (J.A.A.); Jagiellonian University Medical College, John Paul II Hospital, Krakow, Poland (J.K., P.K.); the University Hospital Cologne, Department of Internal Medicine, Center for Integrated Oncology Aachen-Bonn-Cologne-Duesseldorf, Gastrointestinal Cancer Group Cologne, Cologne (T.Z.), and University Medical Center of Johannes Gutenberg-University Mainz (M.M.) - both in Germany; University Hospitals Gasthuisberg Leuven and KU Leuven, Leuven (E.V.C.), and Ghent University Hospital, Ghent (K.G.) - both in Belgium; University Lille, Claude Huriez University Hospital, Lille (G.P.), and Pontchaillou University Hospital, Department of Gastroenterology, University of Rennes 1, INSERM Unité 1242, Rennes (A.L.) - both in France; Fundación Favaloro, Buenos Aires (G.M.); Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore (J.F.); Akita University Hospital, Akita, Japan (S.M.); Duke Cancer Institute, Durham, NC (H.U.); Princess Margaret Cancer Centre, Toronto (E.E.), and Queen Elizabeth II Health Sciences Centre, Halifax, NS (S.S.) - both in Canada; the Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam (C.G.); Florida Cancer Specialists and Research Institute, Fort Myers (S.Z.); University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco (A.H.K.); St. John of God Murdoch Hospital, Murdoch, WA, Australia (K.F.); Sfantul Nectarie Oncology Center, Craiova, Romania (M.S.); Bristol Myers Squibb, Princeton, NJ (J.Z., L.Z., M.L., P.S., K.K.); and Dana-Farber Cancer Institute, Boston (J.M.C.).
Feliciano J; From the Charles A. Sammons Cancer Center at Baylor University Medical Center, Dallas (R.J.K.), and the University of Texas M.D. Anderson Cancer Center, Houston (J.A.A.); Jagiellonian University Medical College, John Paul II Hospital, Krakow, Poland (J.K., P.K.); the University Hospital Cologne, Department of Internal Medicine, Center for Integrated Oncology Aachen-Bonn-Cologne-Duesseldorf, Gastrointestinal Cancer Group Cologne, Cologne (T.Z.), and University Medical Center of Johannes Gutenberg-University Mainz (M.M.) - both in Germany; University Hospitals Gasthuisberg Leuven and KU Leuven, Leuven (E.V.C.), and Ghent University Hospital, Ghent (K.G.) - both in Belgium; University Lille, Claude Huriez University Hospital, Lille (G.P.), and Pontchaillou University Hospital, Department of Gastroenterology, University of Rennes 1, INSERM Unité 1242, Rennes (A.L.) - both in France; Fundación Favaloro, Buenos Aires (G.M.); Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore (J.F.); Akita University Hospital, Akita, Japan (S.M.); Duke Cancer Institute, Durham, NC (H.U.); Princess Margaret Cancer Centre, Toronto (E.E.), and Queen Elizabeth II Health Sciences Centre, Halifax, NS (S.S.) - both in Canada; the Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam (C.G.); Florida Cancer Specialists and Research Institute, Fort Myers (S.Z.); University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco (A.H.K.); St. John of God Murdoch Hospital, Murdoch, WA, Australia (K.F.); Sfantul Nectarie Oncology Center, Craiova, Romania (M.S.); Bristol Myers Squibb, Princeton, NJ (J.Z., L.Z., M.L., P.S., K.K.); and Dana-Farber Cancer Institute, Boston (J.M.C.).
Motoyama S; From the Charles A. Sammons Cancer Center at Baylor University Medical Center, Dallas (R.J.K.), and the University of Texas M.D. Anderson Cancer Center, Houston (J.A.A.); Jagiellonian University Medical College, John Paul II Hospital, Krakow, Poland (J.K., P.K.); the University Hospital Cologne, Department of Internal Medicine, Center for Integrated Oncology Aachen-Bonn-Cologne-Duesseldorf, Gastrointestinal Cancer Group Cologne, Cologne (T.Z.), and University Medical Center of Johannes Gutenberg-University Mainz (M.M.) - both in Germany; University Hospitals Gasthuisberg Leuven and KU Leuven, Leuven (E.V.C.), and Ghent University Hospital, Ghent (K.G.) - both in Belgium; University Lille, Claude Huriez University Hospital, Lille (G.P.), and Pontchaillou University Hospital, Department of Gastroenterology, University of Rennes 1, INSERM Unité 1242, Rennes (A.L.) - both in France; Fundación Favaloro, Buenos Aires (G.M.); Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore (J.F.); Akita University Hospital, Akita, Japan (S.M.); Duke Cancer Institute, Durham, NC (H.U.); Princess Margaret Cancer Centre, Toronto (E.E.), and Queen Elizabeth II Health Sciences Centre, Halifax, NS (S.S.) - both in Canada; the Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam (C.G.); Florida Cancer Specialists and Research Institute, Fort Myers (S.Z.); University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco (A.H.K.); St. John of God Murdoch Hospital, Murdoch, WA, Australia (K.F.); Sfantul Nectarie Oncology Center, Craiova, Romania (M.S.); Bristol Myers Squibb, Princeton, NJ (J.Z., L.Z., M.L., P.S., K.K.); and Dana-Farber Cancer Institute, Boston (J.M.C.).
Lièvre A; From the Charles A. Sammons Cancer Center at Baylor University Medical Center, Dallas (R.J.K.), and the University of Texas M.D. Anderson Cancer Center, Houston (J.A.A.); Jagiellonian University Medical College, John Paul II Hospital, Krakow, Poland (J.K., P.K.); the University Hospital Cologne, Department of Internal Medicine, Center for Integrated Oncology Aachen-Bonn-Cologne-Duesseldorf, Gastrointestinal Cancer Group Cologne, Cologne (T.Z.), and University Medical Center of Johannes Gutenberg-University Mainz (M.M.) - both in Germany; University Hospitals Gasthuisberg Leuven and KU Leuven, Leuven (E.V.C.), and Ghent University Hospital, Ghent (K.G.) - both in Belgium; University Lille, Claude Huriez University Hospital, Lille (G.P.), and Pontchaillou University Hospital, Department of Gastroenterology, University of Rennes 1, INSERM Unité 1242, Rennes (A.L.) - both in France; Fundación Favaloro, Buenos Aires (G.M.); Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore (J.F.); Akita University Hospital, Akita, Japan (S.M.); Duke Cancer Institute, Durham, NC (H.U.); Princess Margaret Cancer Centre, Toronto (E.E.), and Queen Elizabeth II Health Sciences Centre, Halifax, NS (S.S.) - both in Canada; the Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam (C.G.); Florida Cancer Specialists and Research Institute, Fort Myers (S.Z.); University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco (A.H.K.); St. John of God Murdoch Hospital, Murdoch, WA, Australia (K.F.); Sfantul Nectarie Oncology Center, Craiova, Romania (M.S.); Bristol Myers Squibb, Princeton, NJ (J.Z., L.Z., M.L., P.S., K.K.); and Dana-Farber Cancer Institute, Boston (J.M.C.).
Uronis H; From the Charles A. Sammons Cancer Center at Baylor University Medical Center, Dallas (R.J.K.), and the University of Texas M.D. Anderson Cancer Center, Houston (J.A.A.); Jagiellonian University Medical College, John Paul II Hospital, Krakow, Poland (J.K., P.K.); the University Hospital Cologne, Department of Internal Medicine, Center for Integrated Oncology Aachen-Bonn-Cologne-Duesseldorf, Gastrointestinal Cancer Group Cologne, Cologne (T.Z.), and University Medical Center of Johannes Gutenberg-University Mainz (M.M.) - both in Germany; University Hospitals Gasthuisberg Leuven and KU Leuven, Leuven (E.V.C.), and Ghent University Hospital, Ghent (K.G.) - both in Belgium; University Lille, Claude Huriez University Hospital, Lille (G.P.), and Pontchaillou University Hospital, Department of Gastroenterology, University of Rennes 1, INSERM Unité 1242, Rennes (A.L.) - both in France; Fundación Favaloro, Buenos Aires (G.M.); Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore (J.F.); Akita University Hospital, Akita, Japan (S.M.); Duke Cancer Institute, Durham, NC (H.U.); Princess Margaret Cancer Centre, Toronto (E.E.), and Queen Elizabeth II Health Sciences Centre, Halifax, NS (S.S.) - both in Canada; the Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam (C.G.); Florida Cancer Specialists and Research Institute, Fort Myers (S.Z.); University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco (A.H.K.); St. John of God Murdoch Hospital, Murdoch, WA, Australia (K.F.); Sfantul Nectarie Oncology Center, Craiova, Romania (M.S.); Bristol Myers Squibb, Princeton, NJ (J.Z., L.Z., M.L., P.S., K.K.); and Dana-Farber Cancer Institute, Boston (J.M.C.).
Elimova E; From the Charles A. Sammons Cancer Center at Baylor University Medical Center, Dallas (R.J.K.), and the University of Texas M.D. Anderson Cancer Center, Houston (J.A.A.); Jagiellonian University Medical College, John Paul II Hospital, Krakow, Poland (J.K., P.K.); the University Hospital Cologne, Department of Internal Medicine, Center for Integrated Oncology Aachen-Bonn-Cologne-Duesseldorf, Gastrointestinal Cancer Group Cologne, Cologne (T.Z.), and University Medical Center of Johannes Gutenberg-University Mainz (M.M.) - both in Germany; University Hospitals Gasthuisberg Leuven and KU Leuven, Leuven (E.V.C.), and Ghent University Hospital, Ghent (K.G.) - both in Belgium; University Lille, Claude Huriez University Hospital, Lille (G.P.), and Pontchaillou University Hospital, Department of Gastroenterology, University of Rennes 1, INSERM Unité 1242, Rennes (A.L.) - both in France; Fundación Favaloro, Buenos Aires (G.M.); Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore (J.F.); Akita University Hospital, Akita, Japan (S.M.); Duke Cancer Institute, Durham, NC (H.U.); Princess Margaret Cancer Centre, Toronto (E.E.), and Queen Elizabeth II Health Sciences Centre, Halifax, NS (S.S.) - both in Canada; the Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam (C.G.); Florida Cancer Specialists and Research Institute, Fort Myers (S.Z.); University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco (A.H.K.); St. John of God Murdoch Hospital, Murdoch, WA, Australia (K.F.); Sfantul Nectarie Oncology Center, Craiova, Romania (M.S.); Bristol Myers Squibb, Princeton, NJ (J.Z., L.Z., M.L., P.S., K.K.); and Dana-Farber Cancer Institute, Boston (J.M.C.).
Grootscholten C; From the Charles A. Sammons Cancer Center at Baylor University Medical Center, Dallas (R.J.K.), and the University of Texas M.D. Anderson Cancer Center, Houston (J.A.A.); Jagiellonian University Medical College, John Paul II Hospital, Krakow, Poland (J.K., P.K.); the University Hospital Cologne, Department of Internal Medicine, Center for Integrated Oncology Aachen-Bonn-Cologne-Duesseldorf, Gastrointestinal Cancer Group Cologne, Cologne (T.Z.), and University Medical Center of Johannes Gutenberg-University Mainz (M.M.) - both in Germany; University Hospitals Gasthuisberg Leuven and KU Leuven, Leuven (E.V.C.), and Ghent University Hospital, Ghent (K.G.) - both in Belgium; University Lille, Claude Huriez University Hospital, Lille (G.P.), and Pontchaillou University Hospital, Department of Gastroenterology, University of Rennes 1, INSERM Unité 1242, Rennes (A.L.) - both in France; Fundación Favaloro, Buenos Aires (G.M.); Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore (J.F.); Akita University Hospital, Akita, Japan (S.M.); Duke Cancer Institute, Durham, NC (H.U.); Princess Margaret Cancer Centre, Toronto (E.E.), and Queen Elizabeth II Health Sciences Centre, Halifax, NS (S.S.) - both in Canada; the Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam (C.G.); Florida Cancer Specialists and Research Institute, Fort Myers (S.Z.); University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco (A.H.K.); St. John of God Murdoch Hospital, Murdoch, WA, Australia (K.F.); Sfantul Nectarie Oncology Center, Craiova, Romania (M.S.); Bristol Myers Squibb, Princeton, NJ (J.Z., L.Z., M.L., P.S., K.K.); and Dana-Farber Cancer Institute, Boston (J.M.C.).
Geboes K; From the Charles A. Sammons Cancer Center at Baylor University Medical Center, Dallas (R.J.K.), and the University of Texas M.D. Anderson Cancer Center, Houston (J.A.A.); Jagiellonian University Medical College, John Paul II Hospital, Krakow, Poland (J.K., P.K.); the University Hospital Cologne, Department of Internal Medicine, Center for Integrated Oncology Aachen-Bonn-Cologne-Duesseldorf, Gastrointestinal Cancer Group Cologne, Cologne (T.Z.), and University Medical Center of Johannes Gutenberg-University Mainz (M.M.) - both in Germany; University Hospitals Gasthuisberg Leuven and KU Leuven, Leuven (E.V.C.), and Ghent University Hospital, Ghent (K.G.) - both in Belgium; University Lille, Claude Huriez University Hospital, Lille (G.P.), and Pontchaillou University Hospital, Department of Gastroenterology, University of Rennes 1, INSERM Unité 1242, Rennes (A.L.) - both in France; Fundación Favaloro, Buenos Aires (G.M.); Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore (J.F.); Akita University Hospital, Akita, Japan (S.M.); Duke Cancer Institute, Durham, NC (H.U.); Princess Margaret Cancer Centre, Toronto (E.E.), and Queen Elizabeth II Health Sciences Centre, Halifax, NS (S.S.) - both in Canada; the Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam (C.G.); Florida Cancer Specialists and Research Institute, Fort Myers (S.Z.); University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco (A.H.K.); St. John of God Murdoch Hospital, Murdoch, WA, Australia (K.F.); Sfantul Nectarie Oncology Center, Craiova, Romania (M.S.); Bristol Myers Squibb, Princeton, NJ (J.Z., L.Z., M.L., P.S., K.K.); and Dana-Farber Cancer Institute, Boston (J.M.C.).
Zafar S; From the Charles A. Sammons Cancer Center at Baylor University Medical Center, Dallas (R.J.K.), and the University of Texas M.D. Anderson Cancer Center, Houston (J.A.A.); Jagiellonian University Medical College, John Paul II Hospital, Krakow, Poland (J.K., P.K.); the University Hospital Cologne, Department of Internal Medicine, Center for Integrated Oncology Aachen-Bonn-Cologne-Duesseldorf, Gastrointestinal Cancer Group Cologne, Cologne (T.Z.), and University Medical Center of Johannes Gutenberg-University Mainz (M.M.) - both in Germany; University Hospitals Gasthuisberg Leuven and KU Leuven, Leuven (E.V.C.), and Ghent University Hospital, Ghent (K.G.) - both in Belgium; University Lille, Claude Huriez University Hospital, Lille (G.P.), and Pontchaillou University Hospital, Department of Gastroenterology, University of Rennes 1, INSERM Unité 1242, Rennes (A.L.) - both in France; Fundación Favaloro, Buenos Aires (G.M.); Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore (J.F.); Akita University Hospital, Akita, Japan (S.M.); Duke Cancer Institute, Durham, NC (H.U.); Princess Margaret Cancer Centre, Toronto (E.E.), and Queen Elizabeth II Health Sciences Centre, Halifax, NS (S.S.) - both in Canada; the Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam (C.G.); Florida Cancer Specialists and Research Institute, Fort Myers (S.Z.); University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco (A.H.K.); St. John of God Murdoch Hospital, Murdoch, WA, Australia (K.F.); Sfantul Nectarie Oncology Center, Craiova, Romania (M.S.); Bristol Myers Squibb, Princeton, NJ (J.Z., L.Z., M.L., P.S., K.K.); and Dana-Farber Cancer Institute, Boston (J.M.C.).
Snow S; From the Charles A. Sammons Cancer Center at Baylor University Medical Center, Dallas (R.J.K.), and the University of Texas M.D. Anderson Cancer Center, Houston (J.A.A.); Jagiellonian University Medical College, John Paul II Hospital, Krakow, Poland (J.K., P.K.); the University Hospital Cologne, Department of Internal Medicine, Center for Integrated Oncology Aachen-Bonn-Cologne-Duesseldorf, Gastrointestinal Cancer Group Cologne, Cologne (T.Z.), and University Medical Center of Johannes Gutenberg-University Mainz (M.M.) - both in Germany; University Hospitals Gasthuisberg Leuven and KU Leuven, Leuven (E.V.C.), and Ghent University Hospital, Ghent (K.G.) - both in Belgium; University Lille, Claude Huriez University Hospital, Lille (G.P.), and Pontchaillou University Hospital, Department of Gastroenterology, University of Rennes 1, INSERM Unité 1242, Rennes (A.L.) - both in France; Fundación Favaloro, Buenos Aires (G.M.); Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore (J.F.); Akita University Hospital, Akita, Japan (S.M.); Duke Cancer Institute, Durham, NC (H.U.); Princess Margaret Cancer Centre, Toronto (E.E.), and Queen Elizabeth II Health Sciences Centre, Halifax, NS (S.S.) - both in Canada; the Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam (C.G.); Florida Cancer Specialists and Research Institute, Fort Myers (S.Z.); University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco (A.H.K.); St. John of God Murdoch Hospital, Murdoch, WA, Australia (K.F.); Sfantul Nectarie Oncology Center, Craiova, Romania (M.S.); Bristol Myers Squibb, Princeton, NJ (J.Z., L.Z., M.L., P.S., K.K.); and Dana-Farber Cancer Institute, Boston (J.M.C.).
Ko AH; From the Charles A. Sammons Cancer Center at Baylor University Medical Center, Dallas (R.J.K.), and the University of Texas M.D. Anderson Cancer Center, Houston (J.A.A.); Jagiellonian University Medical College, John Paul II Hospital, Krakow, Poland (J.K., P.K.); the University Hospital Cologne, Department of Internal Medicine, Center for Integrated Oncology Aachen-Bonn-Cologne-Duesseldorf, Gastrointestinal Cancer Group Cologne, Cologne (T.Z.), and University Medical Center of Johannes Gutenberg-University Mainz (M.M.) - both in Germany; University Hospitals Gasthuisberg Leuven and KU Leuven, Leuven (E.V.C.), and Ghent University Hospital, Ghent (K.G.) - both in Belgium; University Lille, Claude Huriez University Hospital, Lille (G.P.), and Pontchaillou University Hospital, Department of Gastroenterology, University of Rennes 1, INSERM Unité 1242, Rennes (A.L.) - both in France; Fundación Favaloro, Buenos Aires (G.M.); Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore (J.F.); Akita University Hospital, Akita, Japan (S.M.); Duke Cancer Institute, Durham, NC (H.U.); Princess Margaret Cancer Centre, Toronto (E.E.), and Queen Elizabeth II Health Sciences Centre, Halifax, NS (S.S.) - both in Canada; the Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam (C.G.); Florida Cancer Specialists and Research Institute, Fort Myers (S.Z.); University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco (A.H.K.); St. John of God Murdoch Hospital, Murdoch, WA, Australia (K.F.); Sfantul Nectarie Oncology Center, Craiova, Romania (M.S.); Bristol Myers Squibb, Princeton, NJ (J.Z., L.Z., M.L., P.S., K.K.); and Dana-Farber Cancer Institute, Boston (J.M.C.).
Feeney K; From the Charles A. Sammons Cancer Center at Baylor University Medical Center, Dallas (R.J.K.), and the University of Texas M.D. Anderson Cancer Center, Houston (J.A.A.); Jagiellonian University Medical College, John Paul II Hospital, Krakow, Poland (J.K., P.K.); the University Hospital Cologne, Department of Internal Medicine, Center for Integrated Oncology Aachen-Bonn-Cologne-Duesseldorf, Gastrointestinal Cancer Group Cologne, Cologne (T.Z.), and University Medical Center of Johannes Gutenberg-University Mainz (M.M.) - both in Germany; University Hospitals Gasthuisberg Leuven and KU Leuven, Leuven (E.V.C.), and Ghent University Hospital, Ghent (K.G.) - both in Belgium; University Lille, Claude Huriez University Hospital, Lille (G.P.), and Pontchaillou University Hospital, Department of Gastroenterology, University of Rennes 1, INSERM Unité 1242, Rennes (A.L.) - both in France; Fundación Favaloro, Buenos Aires (G.M.); Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore (J.F.); Akita University Hospital, Akita, Japan (S.M.); Duke Cancer Institute, Durham, NC (H.U.); Princess Margaret Cancer Centre, Toronto (E.E.), and Queen Elizabeth II Health Sciences Centre, Halifax, NS (S.S.) - both in Canada; the Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam (C.G.); Florida Cancer Specialists and Research Institute, Fort Myers (S.Z.); University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco (A.H.K.); St. John of God Murdoch Hospital, Murdoch, WA, Australia (K.F.); Sfantul Nectarie Oncology Center, Craiova, Romania (M.S.); Bristol Myers Squibb, Princeton, NJ (J.Z., L.Z., M.L., P.S., K.K.); and Dana-Farber Cancer Institute, Boston (J.M.C.).
Schenker M; From the Charles A. Sammons Cancer Center at Baylor University Medical Center, Dallas (R.J.K.), and the University of Texas M.D. Anderson Cancer Center, Houston (J.A.A.); Jagiellonian University Medical College, John Paul II Hospital, Krakow, Poland (J.K., P.K.); the University Hospital Cologne, Department of Internal Medicine, Center for Integrated Oncology Aachen-Bonn-Cologne-Duesseldorf, Gastrointestinal Cancer Group Cologne, Cologne (T.Z.), and University Medical Center of Johannes Gutenberg-University Mainz (M.M.) - both in Germany; University Hospitals Gasthuisberg Leuven and KU Leuven, Leuven (E.V.C.), and Ghent University Hospital, Ghent (K.G.) - both in Belgium; University Lille, Claude Huriez University Hospital, Lille (G.P.), and Pontchaillou University Hospital, Department of Gastroenterology, University of Rennes 1, INSERM Unité 1242, Rennes (A.L.) - both in France; Fundación Favaloro, Buenos Aires (G.M.); Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore (J.F.); Akita University Hospital, Akita, Japan (S.M.); Duke Cancer Institute, Durham, NC (H.U.); Princess Margaret Cancer Centre, Toronto (E.E.), and Queen Elizabeth II Health Sciences Centre, Halifax, NS (S.S.) - both in Canada; the Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam (C.G.); Florida Cancer Specialists and Research Institute, Fort Myers (S.Z.); University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco (A.H.K.); St. John of God Murdoch Hospital, Murdoch, WA, Australia (K.F.); Sfantul Nectarie Oncology Center, Craiova, Romania (M.S.); Bristol Myers Squibb, Princeton, NJ (J.Z., L.Z., M.L., P.S., K.K.); and Dana-Farber Cancer Institute, Boston (J.M.C.).
Kocon P; From the Charles A. Sammons Cancer Center at Baylor University Medical Center, Dallas (R.J.K.), and the University of Texas M.D. Anderson Cancer Center, Houston (J.A.A.); Jagiellonian University Medical College, John Paul II Hospital, Krakow, Poland (J.K., P.K.); the University Hospital Cologne, Department of Internal Medicine, Center for Integrated Oncology Aachen-Bonn-Cologne-Duesseldorf, Gastrointestinal Cancer Group Cologne, Cologne (T.Z.), and University Medical Center of Johannes Gutenberg-University Mainz (M.M.) - both in Germany; University Hospitals Gasthuisberg Leuven and KU Leuven, Leuven (E.V.C.), and Ghent University Hospital, Ghent (K.G.) - both in Belgium; University Lille, Claude Huriez University Hospital, Lille (G.P.), and Pontchaillou University Hospital, Department of Gastroenterology, University of Rennes 1, INSERM Unité 1242, Rennes (A.L.) - both in France; Fundación Favaloro, Buenos Aires (G.M.); Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore (J.F.); Akita University Hospital, Akita, Japan (S.M.); Duke Cancer Institute, Durham, NC (H.U.); Princess Margaret Cancer Centre, Toronto (E.E.), and Queen Elizabeth II Health Sciences Centre, Halifax, NS (S.S.) - both in Canada; the Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam (C.G.); Florida Cancer Specialists and Research Institute, Fort Myers (S.Z.); University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco (A.H.K.); St. John of God Murdoch Hospital, Murdoch, WA, Australia (K.F.); Sfantul Nectarie Oncology Center, Craiova, Romania (M.S.); Bristol Myers Squibb, Princeton, NJ (J.Z., L.Z., M.L., P.S., K.K.); and Dana-Farber Cancer Institute, Boston (J.M.C.).
Zhang J; From the Charles A. Sammons Cancer Center at Baylor University Medical Center, Dallas (R.J.K.), and the University of Texas M.D. Anderson Cancer Center, Houston (J.A.A.); Jagiellonian University Medical College, John Paul II Hospital, Krakow, Poland (J.K., P.K.); the University Hospital Cologne, Department of Internal Medicine, Center for Integrated Oncology Aachen-Bonn-Cologne-Duesseldorf, Gastrointestinal Cancer Group Cologne, Cologne (T.Z.), and University Medical Center of Johannes Gutenberg-University Mainz (M.M.) - both in Germany; University Hospitals Gasthuisberg Leuven and KU Leuven, Leuven (E.V.C.), and Ghent University Hospital, Ghent (K.G.) - both in Belgium; University Lille, Claude Huriez University Hospital, Lille (G.P.), and Pontchaillou University Hospital, Department of Gastroenterology, University of Rennes 1, INSERM Unité 1242, Rennes (A.L.) - both in France; Fundación Favaloro, Buenos Aires (G.M.); Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore (J.F.); Akita University Hospital, Akita, Japan (S.M.); Duke Cancer Institute, Durham, NC (H.U.); Princess Margaret Cancer Centre, Toronto (E.E.), and Queen Elizabeth II Health Sciences Centre, Halifax, NS (S.S.) - both in Canada; the Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam (C.G.); Florida Cancer Specialists and Research Institute, Fort Myers (S.Z.); University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco (A.H.K.); St. John of God Murdoch Hospital, Murdoch, WA, Australia (K.F.); Sfantul Nectarie Oncology Center, Craiova, Romania (M.S.); Bristol Myers Squibb, Princeton, NJ (J.Z., L.Z., M.L., P.S., K.K.); and Dana-Farber Cancer Institute, Boston (J.M.C.).
Zhu L; From the Charles A. Sammons Cancer Center at Baylor University Medical Center, Dallas (R.J.K.), and the University of Texas M.D. Anderson Cancer Center, Houston (J.A.A.); Jagiellonian University Medical College, John Paul II Hospital, Krakow, Poland (J.K., P.K.); the University Hospital Cologne, Department of Internal Medicine, Center for Integrated Oncology Aachen-Bonn-Cologne-Duesseldorf, Gastrointestinal Cancer Group Cologne, Cologne (T.Z.), and University Medical Center of Johannes Gutenberg-University Mainz (M.M.) - both in Germany; University Hospitals Gasthuisberg Leuven and KU Leuven, Leuven (E.V.C.), and Ghent University Hospital, Ghent (K.G.) - both in Belgium; University Lille, Claude Huriez University Hospital, Lille (G.P.), and Pontchaillou University Hospital, Department of Gastroenterology, University of Rennes 1, INSERM Unité 1242, Rennes (A.L.) - both in France; Fundación Favaloro, Buenos Aires (G.M.); Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore (J.F.); Akita University Hospital, Akita, Japan (S.M.); Duke Cancer Institute, Durham, NC (H.U.); Princess Margaret Cancer Centre, Toronto (E.E.), and Queen Elizabeth II Health Sciences Centre, Halifax, NS (S.S.) - both in Canada; the Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam (C.G.); Florida Cancer Specialists and Research Institute, Fort Myers (S.Z.); University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco (A.H.K.); St. John of God Murdoch Hospital, Murdoch, WA, Australia (K.F.); Sfantul Nectarie Oncology Center, Craiova, Romania (M.S.); Bristol Myers Squibb, Princeton, NJ (J.Z., L.Z., M.L., P.S., K.K.); and Dana-Farber Cancer Institute, Boston (J.M.C.).
Lei M; From the Charles A. Sammons Cancer Center at Baylor University Medical Center, Dallas (R.J.K.), and the University of Texas M.D. Anderson Cancer Center, Houston (J.A.A.); Jagiellonian University Medical College, John Paul II Hospital, Krakow, Poland (J.K., P.K.); the University Hospital Cologne, Department of Internal Medicine, Center for Integrated Oncology Aachen-Bonn-Cologne-Duesseldorf, Gastrointestinal Cancer Group Cologne, Cologne (T.Z.), and University Medical Center of Johannes Gutenberg-University Mainz (M.M.) - both in Germany; University Hospitals Gasthuisberg Leuven and KU Leuven, Leuven (E.V.C.), and Ghent University Hospital, Ghent (K.G.) - both in Belgium; University Lille, Claude Huriez University Hospital, Lille (G.P.), and Pontchaillou University Hospital, Department of Gastroenterology, University of Rennes 1, INSERM Unité 1242, Rennes (A.L.) - both in France; Fundación Favaloro, Buenos Aires (G.M.); Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore (J.F.); Akita University Hospital, Akita, Japan (S.M.); Duke Cancer Institute, Durham, NC (H.U.); Princess Margaret Cancer Centre, Toronto (E.E.), and Queen Elizabeth II Health Sciences Centre, Halifax, NS (S.S.) - both in Canada; the Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam (C.G.); Florida Cancer Specialists and Research Institute, Fort Myers (S.Z.); University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco (A.H.K.); St. John of God Murdoch Hospital, Murdoch, WA, Australia (K.F.); Sfantul Nectarie Oncology Center, Craiova, Romania (M.S.); Bristol Myers Squibb, Princeton, NJ (J.Z., L.Z., M.L., P.S., K.K.); and Dana-Farber Cancer Institute, Boston (J.M.C.).
Singh P; From the Charles A. Sammons Cancer Center at Baylor University Medical Center, Dallas (R.J.K.), and the University of Texas M.D. Anderson Cancer Center, Houston (J.A.A.); Jagiellonian University Medical College, John Paul II Hospital, Krakow, Poland (J.K., P.K.); the University Hospital Cologne, Department of Internal Medicine, Center for Integrated Oncology Aachen-Bonn-Cologne-Duesseldorf, Gastrointestinal Cancer Group Cologne, Cologne (T.Z.), and University Medical Center of Johannes Gutenberg-University Mainz (M.M.) - both in Germany; University Hospitals Gasthuisberg Leuven and KU Leuven, Leuven (E.V.C.), and Ghent University Hospital, Ghent (K.G.) - both in Belgium; University Lille, Claude Huriez University Hospital, Lille (G.P.), and Pontchaillou University Hospital, Department of Gastroenterology, University of Rennes 1, INSERM Unité 1242, Rennes (A.L.) - both in France; Fundación Favaloro, Buenos Aires (G.M.); Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore (J.F.); Akita University Hospital, Akita, Japan (S.M.); Duke Cancer Institute, Durham, NC (H.U.); Princess Margaret Cancer Centre, Toronto (E.E.), and Queen Elizabeth II Health Sciences Centre, Halifax, NS (S.S.) - both in Canada; the Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam (C.G.); Florida Cancer Specialists and Research Institute, Fort Myers (S.Z.); University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco (A.H.K.); St. John of God Murdoch Hospital, Murdoch, WA, Australia (K.F.); Sfantul Nectarie Oncology Center, Craiova, Romania (M.S.); Bristol Myers Squibb, Princeton, NJ (J.Z., L.Z., M.L., P.S., K.K.); and Dana-Farber Cancer Institute, Boston (J.M.C.).
Kondo K; From the Charles A. Sammons Cancer Center at Baylor University Medical Center, Dallas (R.J.K.), and the University of Texas M.D. Anderson Cancer Center, Houston (J.A.A.); Jagiellonian University Medical College, John Paul II Hospital, Krakow, Poland (J.K., P.K.); the University Hospital Cologne, Department of Internal Medicine, Center for Integrated Oncology Aachen-Bonn-Cologne-Duesseldorf, Gastrointestinal Cancer Group Cologne, Cologne (T.Z.), and University Medical Center of Johannes Gutenberg-University Mainz (M.M.) - both in Germany; University Hospitals Gasthuisberg Leuven and KU Leuven, Leuven (E.V.C.), and Ghent University Hospital, Ghent (K.G.) - both in Belgium; University Lille, Claude Huriez University Hospital, Lille (G.P.), and Pontchaillou University Hospital, Department of Gastroenterology, University of Rennes 1, INSERM Unité 1242, Rennes (A.L.) - both in France; Fundación Favaloro, Buenos Aires (G.M.); Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore (J.F.); Akita University Hospital, Akita, Japan (S.M.); Duke Cancer Institute, Durham, NC (H.U.); Princess Margaret Cancer Centre, Toronto (E.E.), and Queen Elizabeth II Health Sciences Centre, Halifax, NS (S.S.) - both in Canada; the Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam (C.G.); Florida Cancer Specialists and Research Institute, Fort Myers (S.Z.); University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco (A.H.K.); St. John of God Murdoch Hospital, Murdoch, WA, Australia (K.F.); Sfantul Nectarie Oncology Center, Craiova, Romania (M.S.); Bristol Myers Squibb, Princeton, NJ (J.Z., L.Z., M.L., P.S., K.K.); and Dana-Farber Cancer Institute, Boston (J.M.C.).
Cleary JM; From the Charles A. Sammons Cancer Center at Baylor University Medical Center, Dallas (R.J.K.), and the University of Texas M.D. Anderson Cancer Center, Houston (J.A.A.); Jagiellonian University Medical College, John Paul II Hospital, Krakow, Poland (J.K., P.K.); the University Hospital Cologne, Department of Internal Medicine, Center for Integrated Oncology Aachen-Bonn-Cologne-Duesseldorf, Gastrointestinal Cancer Group Cologne, Cologne (T.Z.), and University Medical Center of Johannes Gutenberg-University Mainz (M.M.) - both in Germany; University Hospitals Gasthuisberg Leuven and KU Leuven, Leuven (E.V.C.), and Ghent University Hospital, Ghent (K.G.) - both in Belgium; University Lille, Claude Huriez University Hospital, Lille (G.P.), and Pontchaillou University Hospital, Department of Gastroenterology, University of Rennes 1, INSERM Unité 1242, Rennes (A.L.) - both in France; Fundación Favaloro, Buenos Aires (G.M.); Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore (J.F.); Akita University Hospital, Akita, Japan (S.M.); Duke Cancer Institute, Durham, NC (H.U.); Princess Margaret Cancer Centre, Toronto (E.E.), and Queen Elizabeth II Health Sciences Centre, Halifax, NS (S.S.) - both in Canada; the Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam (C.G.); Florida Cancer Specialists and Research Institute, Fort Myers (S.Z.); University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco (A.H.K.); St. John of God Murdoch Hospital, Murdoch, WA, Australia (K.F.); Sfantul Nectarie Oncology Center, Craiova, Romania (M.S.); Bristol Myers Squibb, Princeton, NJ (J.Z., L.Z., M.L., P.S., K.K.); and Dana-Farber Cancer Institute, Boston (J.M.C.).
Moehler M; From the Charles A. Sammons Cancer Center at Baylor University Medical Center, Dallas (R.J.K.), and the University of Texas M.D. Anderson Cancer Center, Houston (J.A.A.); Jagiellonian University Medical College, John Paul II Hospital, Krakow, Poland (J.K., P.K.); the University Hospital Cologne, Department of Internal Medicine, Center for Integrated Oncology Aachen-Bonn-Cologne-Duesseldorf, Gastrointestinal Cancer Group Cologne, Cologne (T.Z.), and University Medical Center of Johannes Gutenberg-University Mainz (M.M.) - both in Germany; University Hospitals Gasthuisberg Leuven and KU Leuven, Leuven (E.V.C.), and Ghent University Hospital, Ghent (K.G.) - both in Belgium; University Lille, Claude Huriez University Hospital, Lille (G.P.), and Pontchaillou University Hospital, Department of Gastroenterology, University of Rennes 1, INSERM Unité 1242, Rennes (A.L.) - both in France; Fundación Favaloro, Buenos Aires (G.M.); Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore (J.F.); Akita University Hospital, Akita, Japan (S.M.); Duke Cancer Institute, Durham, NC (H.U.); Princess Margaret Cancer Centre, Toronto (E.E.), and Queen Elizabeth II Health Sciences Centre, Halifax, NS (S.S.) - both in Canada; the Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam (C.G.); Florida Cancer Specialists and Research Institute, Fort Myers (S.Z.); University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco (A.H.K.); St. John of God Murdoch Hospital, Murdoch, WA, Australia (K.F.); Sfantul Nectarie Oncology Center, Craiova, Romania (M.S.); Bristol Myers Squibb, Princeton, NJ (J.Z., L.Z., M.L., P.S., K.K.); and Dana-Farber Cancer Institute, Boston (J.M.C.).
Pokaż więcej
Corporate Authors :
CheckMate 577 Investigators
Źródło :
The New England journal of medicine [N Engl J Med] 2021 Apr 01; Vol. 384 (13), pp. 1191-1203.
Typ publikacji :
Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Esophagogastric Junction*
Adenocarcinoma/*therapy
Carcinoma, Squamous Cell/*therapy
Esophageal Neoplasms/*therapy
Immune Checkpoint Inhibitors/*therapeutic use
Nivolumab/*therapeutic use
Adenocarcinoma/immunology ; Adenocarcinoma/surgery ; Adult ; Aged ; Aged, 80 and over ; B7-H1 Antigen/antagonists & inhibitors ; B7-H1 Antigen/metabolism ; Chemoradiotherapy, Adjuvant ; Chemotherapy, Adjuvant ; Disease-Free Survival ; Double-Blind Method ; Esophageal Neoplasms/immunology ; Esophageal Neoplasms/surgery ; Female ; Humans ; Immune Checkpoint Inhibitors/adverse effects ; Intention to Treat Analysis ; Kaplan-Meier Estimate ; Male ; Middle Aged ; Neoadjuvant Therapy ; Nivolumab/adverse effects ; Stomach Neoplasms/immunology ; Stomach Neoplasms/surgery ; Stomach Neoplasms/therapy
Czasopismo naukowe
Tytuł :
Evaluation of emergency departments visits in patients treated with immune checkpoint inhibitors.
Autorzy :
Guven DC; Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Turkey. .
Sahin TK; Department of Internal Medicine, Hacettepe University Faculty of Medicine, Ankara, Turkey.
Aksun MS; Department of Internal Medicine, Hacettepe University Faculty of Medicine, Ankara, Turkey.
Taban H; Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Turkey.
Aktepe OH; Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Turkey.
Aksu NM; Deparment of Emergency Medicine, Hacettepe University Faculty of Medicine, Ankara, Turkey.
Akkaş M; Deparment of Emergency Medicine, Hacettepe University Faculty of Medicine, Ankara, Turkey.
Erman M; Department of Preventive Oncology, Hacettepe University Cancer Institute, Ankara, Turkey.
Kilickap S; Department of Preventive Oncology, Hacettepe University Cancer Institute, Ankara, Turkey.
Dizdar O; Department of Preventive Oncology, Hacettepe University Cancer Institute, Ankara, Turkey.
Aksoy S; Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Turkey.
Pokaż więcej
Źródło :
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer [Support Care Cancer] 2021 Apr; Vol. 29 (4), pp. 2029-2035. Date of Electronic Publication: 2020 Aug 26.
Typ publikacji :
Journal Article
MeSH Terms :
Immune Checkpoint Inhibitors/*therapeutic use
Immunotherapy/*methods
Lung Neoplasms/*drug therapy
Emergency Service, Hospital ; Female ; Humans ; Immune Checkpoint Inhibitors/pharmacology ; Male ; Middle Aged ; Retrospective Studies
Czasopismo naukowe
Tytuł :
Nanosonosensitizer-Augmented Sonodynamic Therapy Combined with Checkpoint Blockade for Cancer Immunotherapy.
Autorzy :
Lin X; Department of Neurosurgery, Zhongshan Hospital Xiamen University, Xiamen, 361004, People's Republic of China.
Huang R; Department of Child Health, Women and Children's Hospital, Xiamen University, Xiamen, 361003, People's Republic of China.
Huang Y; Department of Neurosurgery, Zhongshan Hospital Xiamen University, Xiamen, 361004, People's Republic of China.
Wang K; School of Public Health, Xiamen University, Xiamen, 361102, People's Republic of China.
Li H; Department of Neurosurgery, Zhongshan Hospital Xiamen University, Xiamen, 361004, People's Republic of China.
Bao Y; Department of Neurosurgery, Zhongshan Hospital Xiamen University, Xiamen, 361004, People's Republic of China.
Wu C; Department of Thoracic Surgery, Zhongshan Hospital Xiamen University, Xiamen, 361004, People's Republic of China.
Zhang Y; Department of Breast Surgery, Xiamen TCM Hospital, Xiamen, 361001, People's Republic of China.
Tian X; Department of Neurosurgery, Zhongshan Hospital Xiamen University, Xiamen, 361004, People's Republic of China.
Wang X; Fujian Provincial Key Laboratory of Chronic Liver Disease and Hepatocellular Carcinoma, Zhongshan Hospital Xiamen University, Xiamen, 361004, People's Republic of China.
Pokaż więcej
Źródło :
International journal of nanomedicine [Int J Nanomedicine] 2021 Mar 05; Vol. 16, pp. 1889-1899. Date of Electronic Publication: 2021 Mar 05 (Print Publication: 2021).
Typ publikacji :
Journal Article
MeSH Terms :
Immunotherapy*
Ultrasonic Therapy*
Immune Checkpoint Inhibitors/*therapeutic use
Nanoparticles/*chemistry
Neoplasms/*immunology
Neoplasms/*therapy
Animals ; Cell Death/drug effects ; Cell Line, Tumor ; Combined Modality Therapy ; Dendritic Cells/drug effects ; Endocytosis/drug effects ; Female ; Humans ; Immune Checkpoint Inhibitors/pharmacology ; Immunity/drug effects ; Mice, Inbred BALB C ; Mice, Inbred C57BL ; Nanoparticles/ultrastructure ; Neoplasms/pathology ; Oligodeoxyribonucleotides/chemistry ; Porphyrins/chemistry ; Reactive Oxygen Species/metabolism ; Titanium/chemistry
Czasopismo naukowe
Tytuł :
Clinical Outcomes of Metastatic Renal Carcinoma Following Disease Progression to Programmed Death (PD)-1 or PD-L1 Inhibitors (IO): A Meet-URO Group Real World Study (Meet-Uro 7).
Autorzy :
Santini D; Department of Medical Oncology, Campus Bio-Medico University of Rome, Rome.
Stellato M; Department of Medical Oncology, Campus Bio-Medico University of Rome, Rome.; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan.
De Giorgi U; Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), IRCCS, Meldola.
Pantano F; Department of Medical Oncology, Campus Bio-Medico University of Rome, Rome.
De Lisi D; Department of Medical Oncology, Santa Chiara Hospital, Trento.
Casadei C; Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), IRCCS, Meldola.
Maruzzo M; Medical Oncology Unit 1, Department of Oncology, Istituto Oncologico Veneto IOV IRCCS.
Bimbatti D; Medical Oncology Unit 1, Department of Oncology, Istituto Oncologico Veneto IOV IRCCS.
Naglieri E; Division of Medical Oncology, Istituto Tumori Bari Giovanni Paolo II-IRCCS, Bari.
Buti S; Medical Oncology Unit, University Hospital of Parma, Parma.
Bersanelli M; Medical Oncology Unit, University Hospital of Parma, Parma.
De Vivo R; Department of Oncology, San Bortolo General Hospital, Vicenza.
Di Lorenzo G; Azienda Ospedaliera Universitaria Federico II, Naples.
Sbrana A; Department of Translational Research and New Technologies in Medicine and Surgery, Unit of Medical Oncology 2, Azienda Ospedaliera Universitaria Pisana, Pisa.
Verzoni E; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan.
Soraru' M; Oncology Unit, Camposampiero General Hospital, Camposampiero, Padua.
Fornarini G; Medical Oncology Unit, IRCCS Azienda Ospedaliera Universitaria San Martino-IST Istituto Nazionale per la Ricerca sul Cancro, Genova.
Mucciarini C; U.O. Medicina Oncologica, Ospedale Ramazzini, Carpi-AUSL Modena, Carpi.
Grillone F; Azienda Ospedaliero-Universitario 'Mater Domini,' Policlinico of Catanzaro, Catanzaro.
Mini E; Department of Health Sciences, University of Florence, Firenze.
Vignani F; SCDU Oncologia, AO Ordine Mauriziano, Turin.
Attademo L; Department of Urology and Gynecology, Istituto Nazionale Tumori IRCCS Fondazione 'G. Pascale,' Napoli, Italy.
Pignata S; Department of Urology and Gynecology, Istituto Nazionale Tumori IRCCS Fondazione 'G. Pascale,' Napoli, Italy.
Procopio G; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan.
Pokaż więcej
Źródło :
American journal of clinical oncology [Am J Clin Oncol] 2021 Mar 01; Vol. 44 (3), pp. 121-125.
Typ publikacji :
Journal Article
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Carcinoma, Renal Cell/*drug therapy
Immune Checkpoint Inhibitors/*therapeutic use
Kidney Neoplasms/*drug therapy
Aged ; Anilides/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Carcinoma, Renal Cell/mortality ; Carcinoma, Renal Cell/pathology ; Disease Progression ; Everolimus/administration & dosage ; Female ; Humans ; Immune Checkpoint Inhibitors/adverse effects ; Italy ; Kidney Neoplasms/mortality ; Kidney Neoplasms/pathology ; Male ; Middle Aged ; Nivolumab/adverse effects ; Nivolumab/therapeutic use ; Programmed Cell Death 1 Receptor/metabolism ; Pyridines/administration & dosage ; Retrospective Studies ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Immunotherapy for the treatment of colorectal cancer.
Autorzy :
Lumish MA; Memorial Sloan Kettering Cancer Center, New York, New York.
Cercek A; Memorial Sloan Kettering Cancer Center, New York, New York.
Pokaż więcej
Źródło :
Journal of surgical oncology [J Surg Oncol] 2021 Mar; Vol. 123 (3), pp. 760-774.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Colorectal Neoplasms/*therapy
Immune Checkpoint Inhibitors/*therapeutic use
Immunotherapy/*methods
Clinical Trials, Phase II as Topic ; Clinical Trials, Phase III as Topic ; Colorectal Neoplasms/immunology ; Colorectal Neoplasms/pathology ; Humans ; Immune Checkpoint Inhibitors/immunology ; Neoplasm Metastasis ; Randomized Controlled Trials as Topic
Czasopismo naukowe
Tytuł :
Immune checkpoint blockade in renal cell carcinoma.
Autorzy :
Rappold PM; Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Silagy AW; Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Kotecha RR; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Hakimi AA; Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Pokaż więcej
Źródło :
Journal of surgical oncology [J Surg Oncol] 2021 Mar; Vol. 123 (3), pp. 739-750.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Carcinoma, Renal Cell/*drug therapy
Immune Checkpoint Inhibitors/*therapeutic use
Kidney Neoplasms/*drug therapy
Carcinoma, Renal Cell/immunology ; Clinical Trials as Topic ; Humans ; Immune Checkpoint Inhibitors/immunology ; Kidney Neoplasms/immunology ; Randomized Controlled Trials as Topic
Czasopismo naukowe
Tytuł :
Editorial: the microscope holds the key to predict need for biologic therapy in immunotherapy-checkpoint inhibitory colitis. Authors' reply.
Autorzy :
Pai RK; Department of Laboratory Medicine & Pathology, Mayo Clinic Arizona, Scottsdale, AZ, USA.
Pai RK; Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Schaeffer DF; Department of Pathology, University of British Columbia, Vancouver, BC, Canada.
Choi WT; Department of Pathology, University of California San Francisco, San Francisco, CA, USA.
Kumarasinghe P; Department of Anatomical Pathology, PathWest Laboratory Medicine and University of Western Australia, Perth, WA, Australia.
Brown I; Envoi Specialist Pathologists, Brisbane, QLD, Australia.; Faculty of Medicine, The University of Queensland, Brisbane, QLD, Australia.
Lauwers GY; Department of Pathology, Henry L. Moffitt Cancer Center & Research Institute, Tampa, FL, USA.
Pokaż więcej
Źródło :
Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2021 Mar; Vol. 53 (5), pp. 638-639.
Typ publikacji :
Editorial; Comment
MeSH Terms :
Colitis*/therapy
Immune Checkpoint Inhibitors*
Biological Therapy ; Humans ; Immunologic Factors ; Immunotherapy
Opinia redakcyjna
Tytuł :
Editorial: the microscope holds the key to predict need for biologic therapy in immunotherapy-checkpoint inhibitor colitis.
Autorzy :
Buckle AD; Department of Gastroenterology, The Royal Melbourne Hospital, Melbourne, Vic., Australia.; Department of Gastroenterology, Peter MacCallum Cancer Centre, Melbourne, Vic., Australia.
Christensen B; Department of Gastroenterology, The Royal Melbourne Hospital, Melbourne, Vic., Australia.
Pokaż więcej
Źródło :
Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2021 Mar; Vol. 53 (5), pp. 636-637.
Typ publikacji :
Editorial; Comment
MeSH Terms :
Colitis*/chemically induced
Colitis*/therapy
Immune Checkpoint Inhibitors*
Humans ; Immunologic Factors ; Immunotherapy
Opinia redakcyjna
Tytuł :
Vaccination and Immune Checkpoint Inhibitors: Does Vaccination Increase the Risk of Immune-related Adverse Events? A Systematic Review of Literature.
Autorzy :
Desage AL; Medical Oncology Department.
Bouleftour W; Medical Oncology Department.
Rivoirard R; Medical Oncology Department.
Magne N; Radiotherapy Department, Lucien Neuwirth Cancerology Institute, Saint Priest en Jarez, France.
Collard O; Medical Oncology Department.
Fournel P; Medical Oncology Department.
Tissot C; Medical Oncology Department.
Pokaż więcej
Źródło :
American journal of clinical oncology [Am J Clin Oncol] 2021 Mar 01; Vol. 44 (3), pp. 109-113.
Typ publikacji :
Journal Article; Systematic Review
MeSH Terms :
Immune Checkpoint Inhibitors/*adverse effects
Immunotherapy/*adverse effects
Neoplasms/*immunology
Vaccines/*adverse effects
Humans ; Immune Checkpoint Inhibitors/therapeutic use ; Immunotherapy/methods ; Influenza Vaccines/adverse effects ; Influenza Vaccines/pharmacology ; Neoplasms/therapy ; Seroconversion ; Tetanus Toxoid/adverse effects ; Tetanus Toxoid/pharmacology ; Vaccines/pharmacology
Czasopismo naukowe
Tytuł :
Real-world data on microsatellite instability status in various unresectable or metastatic solid tumors.
Autorzy :
Akagi K; Department of Molecular Diagnosis and Cancer Prevention, Saitama Cancer Center, Saitama, Japan.
Oki E; Department of Surgery and Science, Graduate School of Medical Science, Kyushu University, Fukuoka, Japan.
Taniguchi H; Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Nakatani K; Department of Molecular and Laboratory Medicine, Mie University Graduate School of Medicine, Tsu, Japan.
Aoki D; Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan.
Kuwata T; Department of Genetic Medicine and Services, National Cancer Center Hospital East, Kashiwa, Japan.
Yoshino T; Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Pokaż więcej
Źródło :
Cancer science [Cancer Sci] 2021 Mar; Vol. 112 (3), pp. 1105-1113. Date of Electronic Publication: 2021 Feb 07.
Typ publikacji :
Journal Article
MeSH Terms :
Microsatellite Instability*
Drug Resistance, Neoplasm/*genetics
Immune Checkpoint Inhibitors/*pharmacology
Neoplasms/*genetics
Adolescent ; Adult ; Age Factors ; Aged ; Aged, 80 and over ; Antibodies, Monoclonal, Humanized ; Child ; Child, Preschool ; Cohort Studies ; DNA Mismatch Repair ; Female ; Humans ; Immune Checkpoint Inhibitors/therapeutic use ; Male ; Middle Aged ; Neoplasms/drug therapy ; Neoplasms/immunology ; Neoplasms/pathology ; Programmed Cell Death 1 Receptor/antagonists & inhibitors ; Programmed Cell Death 1 Receptor/immunology ; Risk Factors ; Sex Factors ; Young Adult
Czasopismo naukowe
Tytuł :
Metformin Liposome-Mediated PD-L1 Downregulation for Amplifying the Photodynamic Immunotherapy Efficacy.
Autorzy :
Xiong W; Department of Urology, Xiangya Hospital, Central South University, Changsha 410008, China.
Qi L; Department of Urology, Xiangya Hospital, Central South University, Changsha 410008, China.
Jiang N; State Key Laboratory of Ophthalmology, Optometry and Vision Science, School of Ophthalmology and Optometry, School of Biomedical Engineering, Wenzhou Medical University, Wenzhou 325027, China.; Wenzhou Institute, University of Chinese Academy of Sciences, Wenzhou 325001, China.
Zhao Q; State Key Laboratory of Ophthalmology, Optometry and Vision Science, School of Ophthalmology and Optometry, School of Biomedical Engineering, Wenzhou Medical University, Wenzhou 325027, China.; Wenzhou Institute, University of Chinese Academy of Sciences, Wenzhou 325001, China.
Chen L; Department of Urology, Xiangya Hospital, Central South University, Changsha 410008, China.
Jiang X; Department of Urology, Xiangya Hospital, Central South University, Changsha 410008, China.
Li Y; Department of Urology, Xiangya Hospital, Central South University, Changsha 410008, China.
Zhou Z; State Key Laboratory of Ophthalmology, Optometry and Vision Science, School of Ophthalmology and Optometry, School of Biomedical Engineering, Wenzhou Medical University, Wenzhou 325027, China.; Wenzhou Institute, University of Chinese Academy of Sciences, Wenzhou 325001, China.
Shen J; State Key Laboratory of Ophthalmology, Optometry and Vision Science, School of Ophthalmology and Optometry, School of Biomedical Engineering, Wenzhou Medical University, Wenzhou 325027, China.; Wenzhou Institute, University of Chinese Academy of Sciences, Wenzhou 325001, China.
Pokaż więcej
Źródło :
ACS applied materials & interfaces [ACS Appl Mater Interfaces] 2021 Feb 24; Vol. 13 (7), pp. 8026-8041. Date of Electronic Publication: 2021 Feb 12.
Typ publikacji :
Journal Article
MeSH Terms :
Immunotherapy*
Photochemotherapy*
Antineoplastic Agents/*pharmacology
B7-H1 Antigen/*antagonists & inhibitors
Immune Checkpoint Inhibitors/*pharmacology
Metformin/*pharmacology
Animals ; Antineoplastic Agents/chemistry ; Apoptosis/drug effects ; B7-H1 Antigen/analysis ; B7-H1 Antigen/metabolism ; Cell Line, Tumor ; Cell Proliferation/drug effects ; Cell Survival/drug effects ; Down-Regulation/drug effects ; Drug Screening Assays, Antitumor ; Immune Checkpoint Inhibitors/chemistry ; Indoles/chemistry ; Indoles/pharmacology ; Liposomes/chemistry ; Liposomes/pharmacology ; Male ; Metformin/chemistry ; Mice ; Mice, Inbred BALB C ; Mice, Inbred C57BL ; Neoplasms, Experimental/diagnostic imaging ; Neoplasms, Experimental/drug therapy ; Neoplasms, Experimental/metabolism ; Optical Imaging ; Particle Size ; Surface Properties ; Tumor Hypoxia/drug effects
Czasopismo naukowe
Tytuł :
Abscopal Effect of Frozen Autograft Reconstruction Combined with an Immune Checkpoint Inhibitor Analyzed Using a Metastatic Bone Tumor Model.
Autorzy :
Yonezawa N; Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kanazawa University, 13-1 Takara-machi, Kanazawa 920-8641, Japan.
Murakami H; Department of Orthopaedic Surgery, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi 467-8601, Japan.
Demura S; Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kanazawa University, 13-1 Takara-machi, Kanazawa 920-8641, Japan.
Kato S; Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kanazawa University, 13-1 Takara-machi, Kanazawa 920-8641, Japan.
Miwa S; Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kanazawa University, 13-1 Takara-machi, Kanazawa 920-8641, Japan.
Yoshioka K; Department of Orthopaedic Surgery, National Hospital Organization Kanazawa Medical Center, Kanazawa, Ishikawa 920-8650, Japan.
Shinmura K; Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kanazawa University, 13-1 Takara-machi, Kanazawa 920-8641, Japan.
Yokogawa N; Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kanazawa University, 13-1 Takara-machi, Kanazawa 920-8641, Japan.
Shimizu T; Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kanazawa University, 13-1 Takara-machi, Kanazawa 920-8641, Japan.
Oku N; Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kanazawa University, 13-1 Takara-machi, Kanazawa 920-8641, Japan.
Kitagawa R; Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kanazawa University, 13-1 Takara-machi, Kanazawa 920-8641, Japan.
Handa M; Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kanazawa University, 13-1 Takara-machi, Kanazawa 920-8641, Japan.
Annen R; Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kanazawa University, 13-1 Takara-machi, Kanazawa 920-8641, Japan.
Kurokawa Y; Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kanazawa University, 13-1 Takara-machi, Kanazawa 920-8641, Japan.
Fushimi K; Department of Gastroenterology, Kanazawa University Hospital, Kanazawa, Ishikawa 920-8641, Japan.
Mizukoshi E; Department of Gastroenterology, Kanazawa University Hospital, Kanazawa, Ishikawa 920-8641, Japan.
Tsuchiya H; Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kanazawa University, 13-1 Takara-machi, Kanazawa 920-8641, Japan.
Pokaż więcej
Źródło :
International journal of molecular sciences [Int J Mol Sci] 2021 Feb 17; Vol. 22 (4). Date of Electronic Publication: 2021 Feb 17.
Typ publikacji :
Journal Article
MeSH Terms :
Autografts/*drug effects
Bone Neoplasms/*drug therapy
Bone Neoplasms/*pathology
Immune Checkpoint Inhibitors/*therapeutic use
Animals ; Bone Neoplasms/immunology ; CD8-Positive T-Lymphocytes/immunology ; Carcinogenesis/pathology ; Cell Proliferation/drug effects ; Disease Models, Animal ; Female ; Immune Checkpoint Inhibitors/pharmacology ; Mice, Inbred C3H ; Neoplasm Metastasis ; Programmed Cell Death 1 Receptor/antagonists & inhibitors ; Programmed Cell Death 1 Receptor/metabolism ; Splenomegaly/pathology ; Tumor Burden/drug effects
Czasopismo naukowe
Tytuł :
Impact of previous thoracsic radiation therapy on the efficacy of immune checkpoint inhibitors in advanced non-smasll-cell lung cancer.
Autorzy :
Hosokawa S; Department of Respiratory Medicine, Japanese Red Cross Okayama Hospital, Okayama, Japan.
Ichihara E; Department of Allergy and Respiratory Medicine, Okayama University Hospital, Okayama, Japan.
Bessho A; Department of Respiratory Medicine, Japanese Red Cross Okayama Hospital, Okayama, Japan.
Harada D; Department of Thoracic Oncology, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan.
Inoue K; Department of Respiratory Medicine, Ehime Prefectural Central Hospital, Matsuyama, Japan.
Shibayama T; Department of Respiratory Medicine, National Hospital Organization Okayama Medical Center, Okayama, Japan.
Kishino D; Department of Respiratory Medicine, Himeji Red Cross Hospital, Himeji, Japan.
Harita S; Department of Internal Medicine, Okayama Saiseikai General Hospital, Okayama, Japan.
Ochi N; Department of General Internal Medicine 4, Kawasaki Medical School, Okayama, Japan.
Oda N; Department of Internal Medicine, Fukuyama City Hospital, Fukuyama, Japan.
Hara N; Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan.
Hotta K; Center for Innovative Clinical Medicine, Okayama University Hospital, Okayama, Japan.
Maeda Y; Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan.
Kiura K; Department of Allergy and Respiratory Medicine, Okayama University Hospital, Okayama, Japan.
Pokaż więcej
Źródło :
Japanese journal of clinical oncology [Jpn J Clin Oncol] 2021 Feb 08; Vol. 51 (2), pp. 279-286.
Typ publikacji :
Journal Article
MeSH Terms :
Carcinoma, Non-Small-Cell Lung/*drug therapy
Carcinoma, Non-Small-Cell Lung/*radiotherapy
Immune Checkpoint Inhibitors/*therapeutic use
Lung Neoplasms/*drug therapy
Lung Neoplasms/*radiotherapy
Thorax/*radiation effects
Adult ; Aged ; Aged, 80 and over ; Antibodies, Monoclonal, Humanized/therapeutic use ; B7-H1 Antigen/metabolism ; Female ; Humans ; Immune Checkpoint Inhibitors/adverse effects ; Male ; Middle Aged ; Multivariate Analysis ; Progression-Free Survival ; Retrospective Studies ; Treatment Outcome
Czasopismo naukowe
Tytuł :
First use of tofacitinib to treat an immune checkpoint inhibitor-induced arthritis.
Autorzy :
Murray K; EULAR Centre for Arthritis and Rheumatic Disease, St. Vincent's University Hospital, Dublin, Ireland.
Floudas A; EULAR Centre for Arthritis and Rheumatic Disease, St. Vincent's University Hospital, Dublin, Ireland.; Molecular Rheumatology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland.
Murray C; Pathology, Oncology and Medicine, University College Dublin, Dublin, Ireland.
Fabre A; Pathology, Oncology and Medicine, University College Dublin, Dublin, Ireland.
Crown J; Pathology, Oncology and Medicine, University College Dublin, Dublin, Ireland.
Fearon U; EULAR Centre for Arthritis and Rheumatic Disease, St. Vincent's University Hospital, Dublin, Ireland.; Molecular Rheumatology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland.
Veale D; EULAR Centre for Arthritis and Rheumatic Disease, St. Vincent's University Hospital, Dublin, Ireland .; Pathology, Oncology and Medicine, University College Dublin, Dublin, Ireland.
Pokaż więcej
Źródło :
BMJ case reports [BMJ Case Rep] 2021 Feb 04; Vol. 14 (2). Date of Electronic Publication: 2021 Feb 04.
Typ publikacji :
Case Reports; Journal Article
MeSH Terms :
Immune Checkpoint Inhibitors*
Arthritis, Rheumatoid/*drug therapy
Piperidines/*therapeutic use
Protein Kinase Inhibitors/*therapeutic use
Pyrimidines/*therapeutic use
Arthritis, Rheumatoid/pathology ; Humans ; Lung Neoplasms ; Male ; Middle Aged ; Precision Medicine
Czasopismo naukowe
Tytuł :
Management of Immunotherapy-Related Toxicities in Patients Treated With Immune Checkpoint Inhibitor Therapy.
Autorzy :
Reid PD; University of Chicago, Chicago, Illinois.
Cifu AS; University of Chicago, Chicago, Illinois.
Bass AR; Hospital for Special Surgery, Weill Cornell Medicine, New York, New York.
Pokaż więcej
Źródło :
JAMA [JAMA] 2021 Feb 02; Vol. 325 (5), pp. 482-483.
Typ publikacji :
Journal Article
MeSH Terms :
Practice Guidelines as Topic*
Drug-Related Side Effects and Adverse Reactions/*therapy
Immune Checkpoint Inhibitors/*adverse effects
Immunotherapy/*adverse effects
Neoplasms/*therapy
Adult ; Humans ; Immune Checkpoint Inhibitors/therapeutic use ; Tumor Necrosis Factor-alpha/antagonists & inhibitors
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies